Merck’s Keytruda meets primary endpoint in urothelial cancer study
A phase 3 study evaluating the use of Merck’s Keytruda (pembrolizumab) immunotherapy in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).
